Quantcast
Last updated on April 23, 2014 at 1:22 EDT

Latest AcelRx Pharmaceuticals Inc. Stories

2013-12-05 08:25:20

NEW YORK, December 5, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Mindray Medical International Limited (NYSE: MR), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), ZELTIQ Aesthetics, Inc. (NASDAQ: ZLTQ), and Clovis Oncology, Inc. (NASDAQ: CLVS). Today's readers may access these reports free of charge -...

2013-12-02 08:30:47

REDWOOD CITY, Calif., Dec. 2, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the Zalviso(TM) New Drug Application (NDA) was accepted for filing by the FDA on November 26, 2013. The acceptance for filing of the NDA indicates the FDA has determined that the application is sufficiently complete to...

2013-11-26 08:27:19

REDWOOD CITY, Calif., Nov. 26, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO, will present a corporate overview at the 25(th) Annual Piper Jaffray Healthcare Conference at the New York Palace in New York, NY. The presentation is scheduled for Wednesday,...

2013-11-05 16:27:11

REDWOOD CITY, Calif., Nov. 5, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and nine months ended September 30, 2013. "With the submission of our NDA at the end of September for Zalviso(TM), AcelRx has commenced activities related to an anticipated U.S. commercial...

2013-10-22 08:32:29

REDWOOD CITY, Calif., Oct. 22, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release third quarter 2013 financial results after market close on Tuesday, November 5, 2013. AcelRx management will host an investment-community conference call at 4:30 p.m. eastern time (1:30 p.m....

2013-10-15 08:30:36

First medical meeting data presentations from Phase 3 clinical trial conducted in orthopedic surgery patients REDWOOD CITY, Calif., Oct. 15, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced presentations of its previously reported Phase 3 data for Zalviso(TM) (sufentanil sublingual microtablet system) at...

2013-10-08 08:28:50

Patent estate includes nine issued U.S. patents, nineteen patents worldwide REDWOOD CITY, Calif., Oct. 8, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today provided an update regarding its growing patent estate which totals 19 issued patents worldwide. These issued patents cover AcelRx's sufentanil...

2013-09-30 08:28:57

Zalviso NDA submitted for the management of moderate-to-severe acute pain in adult patients in the hospital setting REDWOOD CITY, Calif., Sept. 30, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Zalviso(TM)...

2013-09-04 08:31:04

REDWOOD CITY, Calif., Sept. 4, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that David H. Chung has joined the company as chief commercial officer effective September 2, 2013. Mr. Chung brings over 20 years of hospital-focused, global medical device and pharmaceutical sales and marketing...

2013-08-30 12:22:50

REDWOOD CITY, Calif., Aug. 30, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO, will present a corporate overview at the Stifel Healthcare Conference 2013 at the Four Seasons Hotel in Boston, MA. The presentation is scheduled for Wednesday, September 11, 2013...